AI Engines For more Details: Perplexity Kagi Labs You
Skin and Soft Tissue Infections: Dicloxacillin is commonly used to treat skin and soft tissue infections caused by susceptible Staphylococcus aureus bacteria, including impetigo, cellulitis, furuncles (boils), and abscesses.
Staphylococcal Infections: Dicloxacillin is particularly effective against infections caused by beta-lactamase-producing strains of Staphylococcus aureus, including methicillin-sensitive Staphylococcus aureus (MSSA).
Respiratory Tract Infections: Dicloxacillin may be used to treat respiratory tract infections caused by susceptible bacteria, such as Streptococcus pneumoniae and Streptococcus pyogenes. This includes conditions like pharyngitis (sore throat), tonsillitis, and pneumonia.
Bone and Joint Infections: Dicloxacillin can be used as part of the treatment regimen for bone and joint infections caused by susceptible bacteria, including osteomyelitis (bone infection) and septic arthritis.
Endocarditis Prophylaxis: Dicloxacillin may be prescribed to prevent bacterial endocarditis in individuals at risk, such as those with certain heart conditions, before certain dental or surgical procedures.
Other Infections: Dicloxacillin may be used to treat other infections caused by susceptible bacteria, such as urinary tract infections (UTIs) and bacteremia (bloodstream infections).
Precautions and Side Effects: Common side effects of dicloxacillin include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Allergic reactions such as rash, itching, and hives may occur, and severe allergic reactions (anaphylaxis) are possible but rare. Like other penicillin antibiotics, dicloxacillin can cause hypersensitivity reactions, including serious skin reactions and anaphylaxis, in individuals with a history of penicillin allergy.
Resistance: Overuse or inappropriate use of dicloxacillin can lead to the development of antibiotic resistance, reducing its effectiveness in treating infections. Therefore, it is essential to use dicloxacillin judiciously and in accordance with local antimicrobial resistance patterns and guidelines.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0.5 | -0.5 | |
ADHD | 7.3 | 1 | 6.3 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.4 | 1.5 |
Allergic Rhinitis (Hay Fever) | 2.4 | 2.5 | -0.04 |
Allergies | 6.2 | 4.5 | 0.38 |
Allergy to milk products | 1.7 | 1 | 0.7 |
Alopecia (Hair Loss) | 2 | 2 | |
Alzheimer's disease | 5.1 | 8.4 | -0.65 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.2 | 1.8 | 1.89 |
Ankylosing spondylitis | 4.9 | 2.9 | 0.69 |
Anorexia Nervosa | 0.4 | 3.4 | -7.5 |
Antiphospholipid syndrome (APS) | 2.2 | 0.1 | 21 |
Asthma | 2 | 2.4 | -0.2 |
Atherosclerosis | 2 | 3.5 | -0.75 |
Atrial fibrillation | 5.1 | 2.5 | 1.04 |
Autism | 15.6 | 13.8 | 0.13 |
Barrett esophagus cancer | 0.8 | 0.5 | 0.6 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.5 | 2.3 | -0.53 |
Brain Trauma | 1 | 0.9 | 0.11 |
Carcinoma | 5 | 3.8 | 0.32 |
Celiac Disease | 3.1 | 5.7 | -0.84 |
Cerebral Palsy | 2.3 | 1.9 | 0.21 |
Chronic Fatigue Syndrome | 8.7 | 9.2 | -0.06 |
Chronic Kidney Disease | 3.4 | 3 | 0.13 |
Chronic Lyme | 0.9 | -0.9 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.3 | 1.5 | 1.2 |
Chronic Urticaria (Hives) | 1.9 | 2.5 | -0.32 |
Coagulation / Micro clot triggering bacteria | 1.4 | 2 | -0.43 |
Colorectal Cancer | 6.2 | 1.5 | 3.13 |
Constipation | 2.1 | 1 | 1.1 |
Coronary artery disease | 2.5 | 1.3 | 0.92 |
COVID-19 | 16.8 | 22.1 | -0.32 |
Crohn's Disease | 11.2 | 8.7 | 0.29 |
cystic fibrosis | 0.5 | 1.4 | -1.8 |
deep vein thrombosis | 0.5 | 1.5 | -2 |
Depression | 14.9 | 13.2 | 0.13 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 1.5 | 3 | -1 |
Endometriosis | 3.8 | 1.8 | 1.11 |
Eosinophilic Esophagitis | 0.5 | 0.3 | 0.67 |
Epilepsy | 4.1 | 4.2 | -0.02 |
Fibromyalgia | 4.2 | 4.4 | -0.05 |
Functional constipation / chronic idiopathic constipation | 7.8 | 5.9 | 0.32 |
gallstone disease (gsd) | 2.9 | 1.5 | 0.93 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 1.5 | 0.53 |
Generalized anxiety disorder | 2.5 | 2.9 | -0.16 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.8 | 2 | -0.11 |
Halitosis | 1.2 | 0.5 | 1.4 |
Hashimoto's thyroiditis | 3.9 | 1 | 2.9 |
Hidradenitis Suppurativa | 1.1 | 0.3 | 2.67 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.7 | 1.5 | 2.13 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | 0 |
hyperglycemia | 0.2 | 3.3 | -15.5 |
Hyperlipidemia (High Blood Fats) | 1.5 | 0.5 | 2 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 3.4 | 7 | -1.06 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1.3 | 1.3 | |
IgA nephropathy (IgAN) | 6.3 | -6.3 | |
Inflammatory Bowel Disease | 6.3 | 12.9 | -1.05 |
Insomnia | 1.4 | 1.4 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 1.8 | 0.5 | 2.6 |
Irritable Bowel Syndrome | 5.5 | 6.6 | -0.2 |
Liver Cirrhosis | 6.8 | 4.8 | 0.42 |
Long COVID | 12.5 | 12.6 | -0.01 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.1 | 2.5 | -1.27 |
ME/CFS with IBS | 2 | 3.9 | -0.95 |
ME/CFS without IBS | 3.5 | 2.9 | 0.21 |
Menopause | 3 | 3 | |
Metabolic Syndrome | 11.3 | 13.2 | -0.17 |
Mood Disorders | 19.2 | 13.7 | 0.4 |
multiple chemical sensitivity [MCS] | 2.3 | 0.5 | 3.6 |
Multiple Sclerosis | 9.4 | 7.8 | 0.21 |
Multiple system atrophy (MSA) | 3.5 | 1.5 | 1.33 |
Neuropathy (all types) | 1.5 | 0.2 | 6.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 8.4 | -1.27 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 13 | 8.2 | 0.59 |
obsessive-compulsive disorder | 9 | 7.4 | 0.22 |
Osteoarthritis | 3.5 | 0.5 | 6 |
Osteoporosis | 2.4 | 1.9 | 0.26 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 4.8 | 6 | -0.25 |
Polycystic ovary syndrome | 3.4 | 3.5 | -0.03 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.4 | 2.75 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 6.2 | 4.3 | 0.44 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 10.5 | 5.2 | 1.02 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 10.5 | 3 | 2.5 |
scoliosis | 0.5 | 1.6 | -2.2 |
Sjögren syndrome | 4.1 | 4.8 | -0.17 |
Sleep Apnea | 2.5 | 2.4 | 0.04 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1 | 0.3 |
Stress / posttraumatic stress disorder | 4.1 | 4.4 | -0.07 |
Systemic Lupus Erythematosus | 5.8 | 3 | 0.93 |
Tic Disorder | 2 | 2.6 | -0.3 |
Tourette syndrome | 0.5 | 0.4 | 0.25 |
Type 1 Diabetes | 5 | 4 | 0.25 |
Type 2 Diabetes | 11.8 | 10.2 | 0.16 |
Ulcerative colitis | 3.9 | 8.8 | -1.26 |
Unhealthy Ageing | 9.1 | 3.5 | 1.6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.